---
title: Cumulus Oncology - Startup Match Score & Focus Areas
description: Is Cumulus Oncology the right VC for you? See how their thesis aligns with your startup and discover more active investors focusing on oncology and biotech innovation.
---

[![Höpöhöpö_logo_black](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6_logo_black.png)](https://www.hopohopo.io/?hsLang=io)

- [For Startups](https://www.hopohopo.io?hsLang=io)
- For Investors & Accelerators
  
    - [Screen your deal flow with AI](https://www.hopohopo.io/for-investors?hsLang=io)
    - [Source deals from co-investors and accelerators](https://www.hopohopo.io/source-deal-flow?hsLang=io)
    - [Help your portfolio fundraise](https://www.hopohopo.io/portfolio-fundraising?hsLang=io)
- [For BANs](https://www.hopohopo.io/business-angel-networks?hsLang=io)
- [Pricing](https://www.hopohopo.io/pricing?hsLang=io)
- Resources
  
    - [Maritime Venture program](https://maritime-venture.com/)
    - [Startup Fundraising Essentials](https://www.hopohopo.io/fundraising-essentials?hsLang=io)
    - Investor lists 
          - [EdTech investors in Europe](https://www.hopohopo.io/edtech-investors?hsLang=io)
          - [FinTech investors in Europe](https://www.hopohopo.io/fintech-investors?hsLang=io)
          - [HealthTech investors in Europe](https://www.hopohopo.io/healthtech-investors?hsLang=io)
          - [Climate & Sustainability investors](https://www.hopohopo.io/climate-and-sustainability-investors?hsLang=io)
          - [Gaming investors](https://www.hopohopo.io/gaming-investors?hsLang=io)
          - [SpaceTech investors](https://www.hopohopo.io/spacetech-investors?hsLang=io)
          - [SportsTech investors](https://www.hopohopo.io/sporttech-investors?hsLang=io)
          - [Enterprise Software investors](https://www.hopohopo.io/enterprise-software-investors?hsLang=io)
          - [DefSec investors](https://www.hopohopo.io/defsec-investors?hsLang=io)
          - [Marine Tech investors](https://www.hopohopo.io/marinetech-investors?hsLang=io)
          - [Mobility investors](https://www.hopohopo.io/mobility-investors?hsLang=io)
          - [PropTech investors](https://www.hopohopo.io/proptech-investors?hsLang=io)
          - [Energy investors](https://www.hopohopo.io/energy-investors?hsLang=io)
          - [Top 10 Active investors in Berlin](https://www.hopohopo.io/top-investors-berlin?hsLang=io)

[Log in](https://start.hopohopo.io/) [Sign up](https://start.hopohopo.io/?signup=true)

# Cumulus Oncology Overview

 Founded in 2017, Cumulus Oncology is Europe's first oncology biotech creation company, specializing in sourcing novel oncology assets from academic institutes, commercial drug discovery groups, and biopharmaceutical companies. The company identifies and develops new oncology treatments targeting unmet medical needs in specific cancer patient populations. Cumulus operates a 'hub and spoke' model, creating high-value spin-out companies and managing them to key value inflection points. The company incorporates artificial intelligence and machine learning platforms into its decision-making process to prioritize targets and assets, focusing on molecularly selected patient sub-groups. Cumulus has successfully raised significant funding rounds, including a £9 million seed financing in January 2024 led by Eos Advisory and the Scottish National Investment Bank. The company has established spin-out companies such as Nodus Oncology, focusing on DNA damage response therapies, and GIO Therapeutics, targeting GPCRs for oncology and inflammation.

 Is Cumulus Oncology the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Cumulus Oncology, along with a list of other relevant VCs, is available on Hopohopo.io.

## Cumulus Oncology

 VC Fund

![Cumulus Oncology logo](https://www.hopohopo.io/hubfs/ecosystem-logos-from-platform/13452-d6a59bf65feb3c5d8072f370968cfead.png)

## Investment focus

### Invest in

- Baltics
- Nordics
- Western Europe
- Southern Europe
- Central Eastern Europe

### Customer types

- Consumers

### Industries / verticals

- BioTech & Life Sciences
- PharmaTech

Stages

 Seed

First ticket size

 £9,000,000 - £9,000,000

## Contact information

Chief Development Officer

Clare Doris

![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg)

Chief Financial Officer

James Fair

![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg)

Senior Operations Lead

Laura Gallagher

![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg)

Senior Administrator

Nazila Ghandchi

![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg)

Executive in Residence

Dominic James

![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg)

## How to approach funds like Cumulus Oncology

 When approaching Cumulus Oncology, founders should highlight differentiated oncology assets with strong translational potential and a clear path to address defined patient subgroups. Emphasize robust preclinical data, a compelling scientific rationale, and how your asset fits into the current landscape of unmet needs in oncology. Demonstrating openness to collaborative company-building and a willingness to leverage AI-driven decision-making will resonate, as will a readiness to work within a structured, milestone-driven spin-out model.

## Find the best-fitting investors for your startup

 Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing. 

[Find your investor matches](https://start.hopohopo.io/?signup=true)

![Investor funnel board](https://www.hopohopo.io/hubfs/Investor%20list%20web%20page%201.png)

[Check the next investor profile](https://www.hopohopo.io/investors/monen-invest-ab?hsLang=io)

×

![Hopohopo logo](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/HO-Logo_favicon.png)

## Check your match score in Hopohopo.io

 Check how well Cumulus Oncology fits your startup and get a list of the best-fitting investors for your fundraising. 

[Sign up](https://start.hopohopo.io/?signup=true)

×

![Hopohopo logo](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/HO-Logo_favicon.png)

## Check Cumulus Oncology contact details in Hopohopo.io

 Browse all of the contacts related to Cumulus Oncology and send emails directly from your funnel. 

[Sign up](https://start.hopohopo.io/?signup=true)

- [For Startups](https://www.hopohopo.io/startups?hsLang=io)
- [For Investors and Accelerators](https://www.hopohopo.io/business-angels-and-vcs?hsLang=io)
- [For Business Angel Networks](https://www.hopohopo.io/business-angel-networks?hsLang=io)

- [Blog](https://hopohopo.gitbook.io/fundraising-with-hopohopo/)

### Follow us

<https://www.linkedin.com/company/hopohopo-io>

![Höpöhöpö_logo_white](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6_logo_white.png)

© 2026 Hopohopo.io All rights reserved

[Privacy Policy](https://www.hopohopo.io/privacy-policy?hsLang=io)  
[Terms of Service](https://www.hopohopo.io/terms-of-service?hsLang=io) 

![](https://px.ads.linkedin.com/collect/?pid=4090745&fmt=gif)

```json
{
  "@context" : "https://schema.org",
  "@type" : "Organization",
  "description" : "Founded in 2017, Cumulus Oncology is Europe's first oncology biotech creation company, specializing in sourcing novel oncology assets from academic institutes, commercial drug discovery groups, and biopharmaceutical companies. The company identifies and develops new oncology treatments targeting unmet medical needs in specific cancer patient populations. Cumulus operates a 'hub and spoke' model, creating high-value spin-out companies and managing them to key value inflection points. The company incorporates artificial intelligence and machine learning platforms into its decision-making process to prioritize targets and assets, focusing on molecularly selected patient sub-groups. Cumulus has successfully raised significant funding rounds, including a £9 million seed financing in January 2024 led by Eos Advisory and the Scottish National Investment Bank. The company has established spin-out companies such as Nodus Oncology, focusing on DNA damage response therapies, and GIO Therapeutics, targeting GPCRs for oncology and inflammation.",
  "logo" : "https://148519842.fs1.hubspotusercontent-eu1.net/hubfs/148519842/ecosystem-logos-from-platform/13452-d6a59bf65feb3c5d8072f370968cfead.png",
  "name" : "Cumulus Oncology",
  "sameAs" : [ "", "" ],
  "url" : "https://www.cumulusoncology.com/"
}
```